Do prebiotics reduce inflammation?

What reviews found

Reviews measure inflammation through blood markers. The main ones are C-reactive protein (CRP) and signal proteins of the immune system such as tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-6).^[5]

• A 2025 review of 90 trials with 5207 children and adults found lower CRP, TNF-α, IL-1β and IL-6 in adults who took prebiotics or synbiotics. Prebiotics lowered high-sensitivity CRP by a standardized mean difference of -0.50, an effect size with no units.^[1]
• A 2017 review of 68 studies found the same direction for CRP (-0.60). It also reported wide differences between studies: 14 of 29 prebiotic studies found a drop in at least 1 marker, so about half did not.^[5]
• A 2021 review of 12 trials with 535 people with overweight or obesity found CRP lower by 1.06 mg/L and TNF-α lower by 0.64 pg/mL, with no change in weight.^[2]
• A 2020 review in the same group found lower CRP with inulin-type fructans, with a standardized mean difference of -0.31.^[6]

Trials in people with diabetes or metabolic syndrome

Three trials gave 10 g a day for 8 to 12 weeks:^[7][8][9]

• Inulin in 49 women with type 2 diabetes, 8 weeks: high-sensitivity CRP fell by 35.6% and TNF-α by 23.1% compared with the control group.^[7]
• Resistant dextrin in 55 women with type 2 diabetes, 8 weeks: IL-6 fell by 28.4% and TNF-α by 18.8%. The fall in high-sensitivity CRP was not statistically significant.^[8]
• A blend of prebiotics in 60 people with metabolic syndrome, 12 weeks: high-sensitivity CRP changed by -0.58 against +0.37 in the control group. Both groups received healthy eating advice. This was an open-label pilot trial, so people knew what they took.^[9]

A 2020 review of 27 publications in type 2 diabetes called the evidence fair. Most participants were women, and trials lasted at most 12 weeks. Nine publications reported better inflammatory markers.^[10]

Where the results were weak

• Healthy people: a 2026 review found that the effect of prebiotics on systemic inflammation was inconsistent.^[3]
• Older adults: a 2019 review of 10 trials with 689 people found no significant drop in any marker. These trials tested treatments aimed at gut bacteria in general.^[4]
• Gut and blood markers together: in a 2025 review of 36 studies of prebiotics, probiotics and synbiotics, most studies found no change in fecal calprotectin, TNF-α or high-sensitivity CRP.^[11]

Why it may work

The proposed path has three steps:^[5][12]

1. Bacteria in the colon ferment soluble prebiotic fibers.^[5]
2. Fermentation makes short-chain fatty acids (SCFAs) such as acetate, propionate and butyrate.^[12]
3. SCFAs act on immune cells and reduce the release of signals that promote inflammation.^[12]

A 2026 review calls these mechanisms proposals, and asks for more research to clarify them.^[3]

Inflammatory bowel disease

Inflammatory bowel disease is a different question, because the outcome is remission and not a blood marker. A 2025 review of 17 studies found very low certainty of evidence. One fructo-oligosaccharide, kestose, helped induce remission in ulcerative colitis in a trial of 40 people. Oligofructose-enriched inulin did not, and it caused more flatulence and bloating.^[13] For Crohn's disease, prebiotics were no different from controls.^[13]

What is still unknown

These trials mostly report blood markers, and a lower marker does not by itself show that a person has less disease. Types, doses and groups of people differ widely from trial to trial, and this may explain the mixed results.^[5] Longer trials are also needed: data in type 2 diabetes stop at 12 weeks.^[10]